Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Boston Scientific (NYSE:BSX) in a research note issued to investors on Friday morning,Benzinga reports. Needham & Company LLC currently has a $97.00 target price on the medical equipment provider’s stock.

Several other equities analysts also recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Mizuho reduced their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. TD Cowen cut their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, Citigroup reduced their price target on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $106.27.

Boston Scientific Stock Performance

NYSE:BSX opened at $69.54 on Friday. The stock’s 50-day moving average is $79.74 and its 200-day moving average is $92.15. Boston Scientific has a 1-year low of $67.56 and a 1-year high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock has a market cap of $103.34 billion, a P/E ratio of 35.84, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business earned $0.70 EPS. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. raised its stake in Boston Scientific by 70.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 595,938 shares of the medical equipment provider’s stock worth $56,823,000 after buying an additional 247,097 shares during the period. Bank of New Hampshire grew its stake in Boston Scientific by 2.4% in the fourth quarter. Bank of New Hampshire now owns 22,159 shares of the medical equipment provider’s stock valued at $2,113,000 after acquiring an additional 523 shares during the period. World Investment Advisors increased its holdings in shares of Boston Scientific by 2.2% during the fourth quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock valued at $1,846,000 after acquiring an additional 411 shares in the last quarter. Farmers National Bank bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $204,000. Finally, Corient Private Wealth LLC raised its position in shares of Boston Scientific by 2.6% during the fourth quarter. Corient Private Wealth LLC now owns 224,554 shares of the medical equipment provider’s stock worth $21,437,000 after purchasing an additional 5,756 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.